Mbp8298    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica14

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
14 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002571-16-GB
(EUCTR)
29/06/200722/02/2005A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Estonia;Finland;Spain;Lithuania;Denmark;Latvia;Netherlands;United Kingdom;Sweden
2NCT00468611
(ClinicalTrials.gov)
June 20071/5/2007Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple SclerosisA Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple SclerosisMultiple Sclerosis, Secondary ProgressiveDrug: MBP8298BioMS Technology Corp.NULLTerminated18 Years65 YearsBoth510Phase 3United States
3NCT00870155
(ClinicalTrials.gov)
February 200726/3/2009A Study for Patients With Multiple SclerosisAn Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisDrug: dirucotideEli Lilly and CompanyBioMS Technology Corp.Terminated18 Years65 YearsBoth546Phase 2;Phase 3Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom
4NCT00869986
(ClinicalTrials.gov)
November 200624/3/2009A Study for Patients With Relapsing Remitting Multiple SclerosisA Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: dirucotide;Drug: placeboEli Lilly and CompanyBioMS Technology Corp.Completed18 Years50 YearsBoth218Phase 2;Phase 3Bulgaria;Poland;Russian Federation;Serbia;Slovakia;Ukraine
5EUCTR2004-002571-16-EE
(EUCTR)
28/09/200609/06/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2004-002571-16-LT
(EUCTR)
27/09/200601/08/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/AA double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/A Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Not Known
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Sweden;Lithuania
7EUCTR2006-001947-70-SK
(EUCTR)
14/09/200608/08/2006A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple SclerosisA Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis Relapsing Remitting Multiple SclerosisProduct Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology Corp.NULLNot RecruitingFemale: yes
Male: yes
215Phase 2Slovakia
8EUCTR2004-002571-16-LV
(EUCTR)
21/07/200624/08/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/AA double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/A Secondary progressive multiple sclerosisProduct Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Not known
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
9EUCTR2004-002571-16-ES
(EUCTR)
20/07/200609/06/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis.A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. Secondary progressive multiple sclerosisProduct Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
10EUCTR2004-002571-16-NL
(EUCTR)
12/06/200605/07/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/AA double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - N/A Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Not known
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2004-002571-16-DK
(EUCTR)
31/05/200618/04/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
12EUCTR2004-002571-16-FI
(EUCTR)
19/04/200627/02/2006A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
13EUCTR2004-002571-16-SE
(EUCTR)
15/08/200521/06/2005A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. - MAESTRO-01 Secondary progressive multiple sclerosis
MedDRA version: 8.1;Level: LLT;Classification code 10063400;Term: Secondary progressive multiple sclerosis
Product Name: MBP8298 Synthetic Peptide
Product Code: MBP8298
INN or Proposed INN: Dirucotide acetate
Other descriptive name: MBP8298 Synthetic Peptide
BioMS Technology CorpNULLNot RecruitingFemale: yes
Male: yes
553Finland;United Kingdom;Netherlands;Denmark;Estonia;Spain;Latvia;Lithuania;Sweden
14NCT00869726
(ClinicalTrials.gov)
December 200424/3/2009A Study for Patients With Secondary Progressive Multiple SclerosisA Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisDrug: dirucotide;Drug: PlaceboEli Lilly and CompanyBioMS Technology Corp.Completed18 Years65 YearsBoth596Phase 2;Phase 3Canada;Denmark;Estonia;Finland;Germany;Latvia;Netherlands;Spain;Sweden;United Kingdom